Post-market Clinical Follow-up Study on the Performance and Safety of Coronary Artery Perfusion Cannula Used During Cardiopulmonary Bypass
1 other identifier
observational
20
0 countries
N/A
Brief Summary
Prior to the implementation of the Medical Device Regulation (MDR), clinical evaluation of older devices was carried out by Notified Bodies (MBs) based on clinical data obtained from equivalent devices, and CE certification was granted to devices exhibiting similar characteristics. Following the transition to the MDR, the European Union Commission's MEDDEV 2.12/2 guidance emphasizes that MBs, which issued CE certificates according to previous practices, should organize Post Marketing Clinical Follow-up (PMCF) studies to verify the performance and safety of the device throughout its lifecycle in accordance with its intended use for which it bears the CE mark. Thus, PMCF studies are planned to demonstrate that medical devices that were previously CE marked according to previous practices are used safely for patients throughout their lifecycles.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jul 2026
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 22, 2026
CompletedFirst Posted
Study publicly available on registry
June 2, 2026
CompletedStudy Start
First participant enrolled
July 1, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2026
Study Completion
Last participant's last visit for all outcomes
October 1, 2026
June 2, 2026
June 1, 2026
2 months
May 22, 2026
June 1, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Presence of bleeding
Primary endpoints are structured to encompass all clinical use outcomes characterizing device performance. Evaluation items directly related to the Bıçakcılar Vent Catheter will be measured using a Likert scale with values ranging from 1 to 5.
It will be measured during the operation up to 6 hours.
Impact of trauma
It will be used a 5-likert scale.
During the operation
Manipulation during placement
It will be used a 5-likert scale.
During the operation
Cannula leakage
It will be used a 5-likert scale.
During the operation
Interventions
The Coronary Artery Perfusion Cannula is designed for the direct administration of cardioplegic solution into the coronary arteries during cardiopulmonary bypass surgery.
Eligibility Criteria
The aim of this study is not to prove a hypothesis defined by a specific objective-numerical expectation, but rather to compile the various outcomes resulting from the use of a medical device using data obtained from all cases collected within a timeframe that is clinically appropriate and sufficient. In this context, a minimum sample size is being established without considering an objective expectation or the Type I and Type II statistical errors accepted in the research. The sample will be constructed by including participants such that, in a 4-option design with two types of operations and two types of cannulas, there will be at least 5 cases even for the option with the fewest patients operated on in consecutive operations.
You may qualify if:
- Patients who have consulted the Department of Cardiovascular Surgery and for whom the physician has decided to perform heart surgery using the cardiopulmonary bypass technique,
- Patients for whom the use of a coronary artery perfusion cannula is planned during surgery
- Patients who, prior to surgery, have provided consent in the "Cardiovascular Surgery Department Information and Consent Form, Use of Patient Data for Educational and Research Purposes" section regarding the use of their data
You may not qualify if:
- Patients with ostial calcification and/or an ostium that is too small for the cannula tip to fit through,
- Patients known to have hypersensitivity to any of the materials used in the device components
- Patients who have difficulty understanding the study and complying with it
- Patients who may pose a conflict of interest (e.g., relatives of employees of the sponsoring company)
- Patients who have participated in any clinical trial within the past 30 days
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Central Study Contacts
Gizem Özdemir Clinical Evaluation Secialist, Biomedical Engineer
CONTACT
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 22, 2026
First Posted
June 2, 2026
Study Start (Estimated)
July 1, 2026
Primary Completion (Estimated)
September 1, 2026
Study Completion (Estimated)
October 1, 2026
Last Updated
June 2, 2026
Record last verified: 2026-06